KOSDAQ

Pharma / Biotech

Defensive Pick

HLB Therapeutics Co.,Ltd.

115450

₩1,499

-5.78%

🕒 Price Jul 29, 12:30 KST

>_ Owl Terminal AnalysisREPORT + CARD

🔒

Grade · score locked

The overall grade and 100-point score are Premium-only. The 6-metric analysis below is free.

See Premium →

⚠️

Investment caution signals

🟠 -64% below 52-week high

Automatic signals from DART filings and price trends. “Filing” items are detected from the last 180 days of electronic disclosures. Verify facts against the original filings/news. Not a buy/sell recommendation.

💰 Valuation at a glance

Yahoo Finance

PER (price/earnings)N/A

Undervalued10×20×Overvalued

Price ÷ EPS. Lower is cheaper vs earnings. Forward-earnings basis.

PBR (price/book)N/A

📊 Price trend

Open in Multi-chart →Yahoo Finance

-4.90%

MA5

🎯 7-metric analysis

Based on latest annual results

🔒Grade, score & detailed radar are Premium-onlyUnlock · See pricing

Value axes (P/E, P/B, EV) are growth- & profitability-adjusted — premium growth names aren’t pinned to zero. (Losses / negative equity stay 0.)

📈 Key metrics

Yahoo Finance

PERPrice/earnings — lower is cheaper

N/A

PBRPrice/book — below 1× means the price is under the company’s net asset value

N/A

ROEReturn on equity — 15%+ is strong

🏢 Peer comparison

Pharma / Biotech

Side by side with the largest names in the same sector. Green beats the sector median.

Stock	PER	PBR	ROE	Dividend
HLB Therapeutics Co.,Ltd.Current	—	—	—	—
ALTEOGEN Inc.	109.3×	34.78×	31.8%	0.1%

🏦 Dividend vs deposit rate

This stock pays no dividend (or has no dividend data), so it isn't directly comparable to a deposit rate. It may be a growth name that relies on price appreciation instead.

As of: Bank of Korea weighted-avg deposit rate · 3.00% (2026-05)

📡 Technical signals

MA5 (5-day)

1,686.2

Price -11.1% (below)

MA20 (20-day)

N/A

RSI(14)

N/A

MA cross

Neutral

No cross

Above the moving averages means short-term bullish; below means bearish. RSI ≥ 70 is overbought and ≤ 30 is oversold.

📰 Related news

Source: Naver Finance (KR) · Yahoo Finance (US) · external article links

📚 Metrics & scoringShow more

PER

Price/earnings = price ÷ EPS

💡 Lower = cheaper vs earnings — core valuation metric

PBR

Price/book = price ÷ BPS

💡 Lower = cheaper vs net assets (adjusted by sector)

ROE

Return on equity = net income ÷ equity

💡 Higher = uses capital efficiently (profitability)

ROIC

Return on invested capital ≈ operating income ÷ total assets

💡 Replaces ROE when equity is distorted by buybacks — total-asset basis is robust

FCF yield

Free cash flow (≈ op. cash flow × 0.8) ÷ market cap

💡 Cash-based value when book value is meaningless · higher is more attractive

Operating margin

Operating income ÷ revenue

💡 Higher = stronger core-business profitability

🔎 Data sources & methodologyShow more

Every score is auto-computed from the public data below. No manual adjustment.

Item	Source	Method · update cadence
Price · volume · 52W	Yahoo Finance	Stored as-is · hourly intraday
Financials (revenue, profit, equity, debt)	Yahoo fundamentalsTimeSeries	Annual + quarterly reported · refreshed over ~1 week
Short-term (TTM) score	Computed (quarterly financials)	Sum of last 4 quarters + YoY momentum vs same quarter a year ago · daily
PER · PBR	Computed (KR)	Market cap ÷ latest annual net income / equity · N/A on loss or capital impairment
Dividend yield	Yahoo Finance	Annual dividend ÷ price · 0% if none
ROE · operating margin · debt ratio